Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2000

View Archived Issues

Immune Network Research will license two Meditech compounds

Final results of ALLHAT published in JAMA

Combined therapy with estrogen and T-cell receptor protein for MS

Researchers report Atrigel containing leuprolide acetate may offer clinical advantages

Pharmacyclics updates status of products in clinical trials

Teijin/TAP gout treatment now also in clinical trials outside Japan

Combination of MDR modulator LY-335979 and docetaxel advances to phase II

Vivus seeks E.U. marketing approval for Alibra

Phthalocyanines and their use in cancer PDT patented by Brown

Ceramide derivatives synthesized at Otsuka may have potential in cognitive disorders, inflammation

Phase III results for Orthovisc disappointing

Acute effects of MCC-555 on gluconeogenesis in hepatocytes

Inhibitor of iNOS attenuates pancreatic beta-cell injury

Vasoactive diadenosine polyphosphates isolated and characterized by German investigators

Human Genome Sciences to begin phase II trials of repifermin in ulcerative colitis

In vivo effects of BMS-189921 on NEP and ACE reported at hypertension meeting

Dosmalfate launched in Spain for prophylaxis of gastric lesions and ulcers

Neisseria outer membrane proteins useful for the therapy, diagnosis of infections

Topical formulations of CMI-392, a dual PAF antagonist and 5-LO inhibitor

Janssen evaluating combination therapies for Alzheimer's disease and psychosis

Anticonvulsants reported useful for alcohol addiction and abuse

Suntory researchers discover novel neuroprotective agents

Antitumor indenoisoquinolines presented in patent literature

New carbapenem antibiotics with broad-spectrum activity prepared at Wyeth Lederle Japan

Antiplatelet effects reported for new cell adhesion inhibitors from Takeda

Orally bioavailable thrombin inhibitors designed at Pfizer

Flt-1 receptor-targeting ribozyme shows good tolerance, favorable pharmacokinetics in the clinic

Genelabs begins NDA submission of GL-701 for treatment of lupus

DMXAA demonstrates antivascular and cytokine-inducing effects in humans

CEP-701 associated mainly with mild to moderate GI toxicity in phase I trial in cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...